T1	Participants 203 394	after four cycles of modern combination chemotherapy in nonbulky involved field (IF/BF) and noninvolved extended-field (EF/IF) sites in patients with intermediate-stage Hodgkin's disease (HD)
T2	Participants 418 518	HD patients in stage I to IIIA with a large mediastinal mass, E stage, or massive spleen involvement
T4	Participants 769 975	In the HD1 trial (1983 to 1988), 146 patients who responded to chemotherapy were randomized to receive 20 Gy (70 patients) or 40 Gy (76 patients) of EF irradiation in all fields outside bulky disease sites.
T3	Participants 976 1110	A cohort of 111 patients who fulfilled the same inclusion criteria in the subsequent trial HD5 (1988 to 1993) were treated with 30 Gy.
T5	Participants 1768 1848	after 4 months of modern polychemotherapy in patients with intermediate-stage HD
